Spread of COVID-19
First written in FY2020. 11 of 13 entries say "Restated". Latest entry: FY2025-H1.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
50 other companies' latest entry also says "Restated".
- FY2025-H1RestatedAnnual report
「No new business or other risks arose during the current interim consolidated accounting period. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
It is stated that there have been no new or material changes to existing risks, including the spread of infectious diseases. - FY2024-Q3RestatedAnnual report
「No new business or other risks arose during the nine months ended 31 December. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
It is stated that there have been no new or material changes to existing business and other risks, including COVID-19. - FY2024-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
It is stated that there have been no new or material changes to existing business and other risks, including COVID-19. - FY2024-Q1RestatedAnnual report
「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
It is stated that there have been no new or material changes to existing business and other risks, including COVID-19. - FY2023ReframedAnnual report
「Although the legal classification of COVID-19 will change to Category 5 from May 2023, if an outbreak of any infectious disease expands globally in the future, the business environment could become challenging, with declines in personal consumption and deterioration in corporate earnings. Concerns include the risk that an infectious disease could cause downside in domestic and overseas economies and the impact of volatility in financial markets, which could affect the performance of our Group.」
The risk has been reorganised from one centred on COVID-19 to a risk covering future global outbreaks of infectious diseases generally, in light of the transition to Category 5. - FY2023-Q3RestatedAnnual report
「No new business or other risks arose during the nine months ended 31 December. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
It is stated that there have been no new or material changes to existing business and other risks, including COVID-19. - FY2023-Q1RestatedAnnual report
「No new business or other risks arose during the three months ended 30 June. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
It is stated that there have been no new or material changes to existing business and other risks, including COVID-19. - FY2022-Q3RestatedAnnual report
「There have been no material changes to the assumptions concerning the impact of COVID-19 described under “Significant Accounting Estimates” in the securities report for the previous consolidated fiscal year-end.」
It is stated that there have been no material changes to the accounting assumptions at the previous fiscal year-end concerning the impact of COVID-19. - FY2022-Q2RestatedAnnual report
「There have been no material changes to the assumptions concerning the impact of COVID-19 described under “Significant Accounting Estimates” in the securities report for the previous consolidated fiscal year-end.」
It is stated that there have been no material changes to the accounting assumptions at the previous fiscal year-end concerning the impact of COVID-19. - FY2022-Q1RestatedAnnual report
「There have been no material changes to the assumptions concerning the impact of COVID-19 described under “Significant Accounting Estimates” in the securities report for the previous consolidated fiscal year-end.」
It is stated that there have been no material changes to the accounting assumptions at the previous fiscal year-end concerning the impact of COVID-19. - FY2021-Q2RestatedAnnual report
「There have been no material changes to the assumptions concerning the impact of COVID-19 described in the additional information section of the securities report for the previous consolidated fiscal year-end.」
It is stated that there have been no material changes to the assumptions at the previous fiscal year-end concerning the impact of COVID-19. - FY2021-Q1RestatedAnnual report
「There have been no material changes to the assumptions concerning the impact of COVID-19 described in the additional information section of the securities report for the previous consolidated fiscal year-end.」
It is stated that there have been no material changes to the assumptions at the previous fiscal year-end concerning the impact of COVID-19. - FY2020First statedAnnual report
「The business environment has become challenging, with declines in personal consumption and deterioration in corporate earnings due to the spread of COVID-19. Concerns include the risk that the infection could cause further downside in domestic and overseas economies and the impact of volatility in financial markets, which could affect the performance of our Group.」
The spread of COVID-19 is presented as a standalone item under business and other risks, with its potential impact on performance through personal consumption, corporate earnings, domestic and overseas economies, and financial markets described.